121 related articles for article (PubMed ID: 16368922)
1. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
2. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
3. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.
Gardner M; Taylor A; Wei G; Calcagni A; Duncan B; Milton A
J Clin Pharmacol; 2006 Jan; 46(1):52-8. PubMed ID: 16397284
[TBL] [Abstract][Full Text] [Related]
6. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects.
Prakash C; Johnson KA; Gardner MJ
Drug Metab Dispos; 2008 Jul; 36(7):1218-26. PubMed ID: 18372400
[TBL] [Abstract][Full Text] [Related]
7. Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe.
Park JY; Kim KA; Park PW; Ha JM
J Clin Pharmacol; 2006 Jan; 46(1):109-14. PubMed ID: 16397290
[TBL] [Abstract][Full Text] [Related]
8. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
Emery MG; Jubert C; Thummel KE; Kharasch ED
J Pharmacol Exp Ther; 1999 Oct; 291(1):213-9. PubMed ID: 10490907
[TBL] [Abstract][Full Text] [Related]
9. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
10. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
11. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
12. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.
Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA
Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610
[TBL] [Abstract][Full Text] [Related]
13. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.
Ouellet D; Bramson C; Carvajal-Gonzalez S; Roman D; Randinitis E; Remmers A; Gardner MJ
Br J Clin Pharmacol; 2006 Jun; 61(6):741-5. PubMed ID: 16722839
[TBL] [Abstract][Full Text] [Related]
14. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits.
Ozolins TR; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):161-70. PubMed ID: 15282737
[TBL] [Abstract][Full Text] [Related]
15. [Changes of CYP2E1 activity in diabetic rat model].
Li L; Zhang Y
Yao Xue Xue Bao; 1998 Dec; 33(12):891-5. PubMed ID: 12016852
[TBL] [Abstract][Full Text] [Related]
16. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats.
Terry KK; Cappon GD; Hurtt ME; Tassinari MS; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):150-60. PubMed ID: 15282736
[TBL] [Abstract][Full Text] [Related]
17. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys.
Lees C; Shen V; Brommage R
Menopause; 2007; 14(1):97-105. PubMed ID: 17075430
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
[TBL] [Abstract][Full Text] [Related]
19. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
20. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]